{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06311045",
            "orgStudyIdInfo": {
                "id": "23-01469"
            },
            "organization": {
                "fullName": "NYU Langone Health",
                "class": "OTHER"
            },
            "briefTitle": "Obstructive Sleep Apnea (OSA) and Sex-Specific Responses to N-acetylcysteine (NAC)",
            "officialTitle": "Basis of Sex-specific Therapeutic Responses to Obstructive Sleep Apnea (OSA): a Trial of N-acetylcysteine (NAC) in Obstructive Sleep Apnea (OSA)",
            "therapeuticArea": [
                "Other"
            ],
            "study": "obstructive-sleep-apnea-osa-and-sex-specific-responses-to-n-acetylcysteine-nac"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-05-07",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-06",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-03-08",
            "studyFirstSubmitQcDate": "2024-03-08",
            "studyFirstPostDateStruct": {
                "date": "2024-03-15",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-20",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-24",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "NYU Langone Health",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Heart, Lung, and Blood Institute (NHLBI)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a randomized controlled trial (RCT) of 4 weeks of study supplement N-acetylcysteine (NAC) versus placebo in persons with significant obstructive sleep apnea (OSA) who are receiving positive airway pressure therapy (PAP), the standard of care therapy. The purpose of the study is to determine if NAC is associated with sex-specific changes in overnight oxidative stress, inflammation, as well as endothelial dysfunction in persons with OSA."
        },
        "conditionsModule": {
            "conditions": [
                "Obstructive Sleep Apnea"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "OTHER",
                "maskingInfo": {
                    "masking": "DOUBLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 206,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "NAC",
                    "type": "EXPERIMENTAL",
                    "description": "Following run-in PAP therapy per standard clinical care for 12 weeks, participants randomized to the NAC arm will also receive the supplement N-acetylcysteine (NAC) for four weeks while remaining on PAP therapy.",
                    "interventionNames": [
                        "Dietary Supplement: N-acetylcysteine (NAC)",
                        "Procedure: Positive Airway Pressure (PAP) Therapy"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "EXPERIMENTAL",
                    "description": "Following run-in PAP therapy per standard clinical care for 12 weeks, participants randomized to the placebo arm will also receive placebo for four weeks while remaining on PAP therapy.",
                    "interventionNames": [
                        "Dietary Supplement: Placebo",
                        "Procedure: Positive Airway Pressure (PAP) Therapy"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DIETARY_SUPPLEMENT",
                    "name": "N-acetylcysteine (NAC)",
                    "description": "Participants will take two NAC 600mg capsules daily for four weeks.",
                    "armGroupLabels": [
                        "NAC"
                    ]
                },
                {
                    "type": "DIETARY_SUPPLEMENT",
                    "name": "Placebo",
                    "description": "Participants will take two placebo 600mg capsules daily for four weeks.",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                },
                {
                    "type": "PROCEDURE",
                    "name": "Positive Airway Pressure (PAP) Therapy",
                    "description": "All participants will receive PAP therapy per standard of care for OSA.",
                    "armGroupLabels": [
                        "NAC",
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Percent Change in Overnight Levels of Glutathione (GSH)",
                    "description": "GSH measured using participant blood samples.",
                    "timeFrame": "Baseline, Final Study Visit (4 Weeks post Initiation of Study Therapy; up to Month 6)"
                },
                {
                    "measure": "Mean Change in Pre- to Post-Sleep GSH Levels",
                    "description": "GSH measured using participant blood samples.",
                    "timeFrame": "Baseline"
                },
                {
                    "measure": "Mean Change in Pre- to Post-Sleep GSH Levels",
                    "description": "GSH measured using participant blood samples.",
                    "timeFrame": "Final Study Visit (4 Weeks post Initiation of Study Therapy; up to Month 6)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Ratio of GSH to oxidized GSH (GSSG) (GSH:GSSG)",
                    "description": "GSH:GSSG measured using participant blood samples.",
                    "timeFrame": "Baseline"
                },
                {
                    "measure": "Ratio of GSH to oxidized GSH (GSSG) (GSH:GSSG)",
                    "description": "GSH:GSSG measured using participant blood samples.",
                    "timeFrame": "Final Study Visit (4 Weeks post Initiation of Study Therapy; up to Month 6)"
                },
                {
                    "measure": "8-Isoprostane Level",
                    "description": "8-isoprostane levels measured using participant blood samples.",
                    "timeFrame": "Baseline"
                },
                {
                    "measure": "8-Isoprostane Level",
                    "description": "8-isoprostane levels measured using participant blood samples.",
                    "timeFrame": "Final Study Visit (4 Weeks post Initiation of Study Therapy; up to Month 6)"
                },
                {
                    "measure": "Plasma Nitrate Level",
                    "description": "Plasma nitrate levels measured using participant blood samples.",
                    "timeFrame": "Baseline"
                },
                {
                    "measure": "Plasma Nitrate Level",
                    "description": "Plasma nitrate levels measured using participant blood samples.",
                    "timeFrame": "Final Study Visit (4 Weeks post Initiation of Study Therapy; up to Month 6)"
                },
                {
                    "measure": "Plasma Nitrite Level",
                    "description": "Plasma nitrite levels measured using participant blood samples.",
                    "timeFrame": "Baseline"
                },
                {
                    "measure": "Plasma Nitrite Level",
                    "description": "Plasma nitrite levels measured using participant blood samples.",
                    "timeFrame": "Final Study Visit (4 Weeks post Initiation of Study Therapy; up to Month 6)"
                },
                {
                    "measure": "Organic Nitrite Level",
                    "description": "Organic nitrite levels measured using participant blood samples.",
                    "timeFrame": "Baseline"
                },
                {
                    "measure": "Organic Nitrite Level",
                    "description": "Organic nitrite levels measured using participant blood samples.",
                    "timeFrame": "Final Study Visit (4 Weeks post Initiation of Study Therapy; up to Month 6)"
                },
                {
                    "measure": "Interleukin 6 (IL-6) Level",
                    "description": "IL-6 levels measured using participant blood samples.",
                    "timeFrame": "Baseline"
                },
                {
                    "measure": "Interleukin 6 (IL-6) Level",
                    "description": "IL-6 levels measured using participant blood samples.",
                    "timeFrame": "Final Study Visit (4 Weeks post Initiation of Study Therapy; up to Month 6)"
                },
                {
                    "measure": "Tumor Necrosis Factor-alpha (TNF\u03b1) Receptor-1 (TNF\u03b1-R1) Level",
                    "description": "TNF\u03b1-R1 levels measured using participant blood samples.",
                    "timeFrame": "Baseline"
                },
                {
                    "measure": "Tumor Necrosis Factor-alpha (TNF\u03b1) Receptor-1 (TNF\u03b1-R1) Level",
                    "description": "TNF\u03b1-R1 levels measured using participant blood samples.",
                    "timeFrame": "Final Study Visit (4 Weeks post Initiation of Study Therapy; up to Month 6)"
                },
                {
                    "measure": "Tumor Necrosis Factor-alpha (TNF\u03b1) Receptor-2 (TNF\u03b1-R2) Level",
                    "description": "TNF\u03b1-R2 levels measured using participant blood samples.",
                    "timeFrame": "Baseline"
                },
                {
                    "measure": "Tumor Necrosis Factor-alpha (TNF\u03b1) Receptor-2 (TNF\u03b1-R2) Level",
                    "description": "TNF\u03b1-R2 levels measured using participant blood samples.",
                    "timeFrame": "Final Study Visit (4 Weeks post Initiation of Study Therapy; up to Month 6)"
                },
                {
                    "measure": "Reactive Hyperemia Index (RHI) Score",
                    "description": "RHI is a measure of endothelial-dependent vasodilation and is assessed using a noninvasive vascular tone measure (EndoPAT\u00ae). RHI reflects endothelial health, with lower scores signifying more dysfunction. RHI less than 1.67 is considered a sign of endothelial dysfunction and RHI equal to or greater than 1.67 is considered normal function.",
                    "timeFrame": "Baseline"
                },
                {
                    "measure": "Reactive Hyperemia Index (RHI) Score",
                    "description": "RHI is a measure of endothelial-dependent vasodilation and is assessed using a noninvasive vascular tone measure (EndoPAT\u00ae). RHI reflects endothelial health, with lower scores signifying more dysfunction. RHI less than 1.67 is considered a sign of endothelial dysfunction and RHI equal to or greater than 1.67 is considered normal function.",
                    "timeFrame": "Final Study Visit (4 Weeks post Initiation of Study Therapy; up to Month 6)"
                },
                {
                    "measure": "Epworth Sleepiness Scale (ESS) Score",
                    "description": "ESS is an 8-item questionnaire assessing usual likelihood of falling asleep during each of eight common activities. Each item is rated on a Likert scale from 0-3. The total score is the sum of responses and ranges from 0-24; higher scores indicate greater subjective daytime sleepiness.",
                    "timeFrame": "Baseline"
                },
                {
                    "measure": "Epworth Sleepiness Scale (ESS) Score",
                    "description": "ESS is an 8-item questionnaire assessing usual likelihood of falling asleep during each of eight common activities. Each item is rated on a Likert scale from 0-3. The total score is the sum of responses and ranges from 0-24; higher scores indicate greater subjective daytime sleepiness.",
                    "timeFrame": "Final Study Visit (4 Weeks post Initiation of Study Therapy; up to Month 6)"
                },
                {
                    "measure": "Insomnia Severity Index (ISI) Score",
                    "description": "ISI is a 7-item questionnaire assessing the nature, severity, and impact of insomnia. Each item is rated on a 5-point Likert scale from 0-4. The total score is the sum of responses and ranges from 0-28. Scores are interpreted as follows: absence of insomnia (0-7); sub-threshold insomnia (8-14); moderate insomnia (15-21); or severe insomnia (21-28).",
                    "timeFrame": "Baseline"
                },
                {
                    "measure": "Insomnia Severity Index (ISI) Score",
                    "description": "ISI is a 7-item questionnaire assessing the nature, severity, and impact of insomnia. Each item is rated on a 5-point Likert scale from 0-4. The total score is the sum of responses and ranges from 0-28. Scores are interpreted as follows: absence of insomnia (0-7); sub-threshold insomnia (8-14); moderate insomnia (15-21); or severe insomnia (22-28).",
                    "timeFrame": "Final Study Visit (4 Weeks post Initiation of Study Therapy; up to Month 6)"
                },
                {
                    "measure": "Fatigue Severity Scale (FSS) Score",
                    "description": "FSS is a 9-item measure of fatigue severity from a variety of medical and neurological disorders. Each item is rated on a Likert scale from 1-7. The total score is the sum of responses and ranges from 9-63, with higher scores indicating greater fatigue.",
                    "timeFrame": "Baseline"
                },
                {
                    "measure": "Fatigue Severity Scale (FSS) Score",
                    "description": "FSS is a 9-item measure of fatigue severity from a variety of medical and neurological disorders. Each item is rated on a Likert scale from 1-7. The total score is the sum of responses and ranges from 9-63, with higher scores indicating greater fatigue.",
                    "timeFrame": "Final Study Visit (4 Weeks post Initiation of Study Therapy; up to Month 6)"
                },
                {
                    "measure": "Pittsburgh Sleep Quality Index (PSQI) Score",
                    "description": "PSQI is a 19-item questionnaire that is routinely used in both clinical and research settings to assess sleep quality over the preceding one month. The total score ranges from 0-21, with higher scores reflecting worse sleep quality.",
                    "timeFrame": "Baseline"
                },
                {
                    "measure": "Pittsburgh Sleep Quality Index (PSQI) Score",
                    "description": "PSQI is a 19-item questionnaire that is routinely used in both clinical and research settings to assess sleep quality over the preceding one month. The total score ranges from 0-21, with higher scores reflecting worse sleep quality.",
                    "timeFrame": "Final Study Visit (4 Weeks post Initiation of Study Therapy; up to Month 6)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Apnea-hypopnea index \u226515 events/hr on portable sleep monitoring\n* HbA1c \\<6.5%\n\nExclusion Criteria:\n\n* Body mass index (BMI) \u226540 kg/m2;\n* Diagnosis of diabetes mellitus, defined as the use of any diabetes medication (including glucagon like peptide \\[GLP\\]-1 agonists) currently or in the previous three months or HbA1c \u22656.5%;\n* Shift work (i.e., working hours that routinely cause sleep initiation after 1:00 a.m.);\n* Another major sleep disorder (i.e., circadian rhythm disorder, any history of narcolepsy, concurrently diagnosed or medication-treated restless legs syndrome, concurrently diagnosed or medication-treated chronic insomnia with the exception of antidepressant therapy);\n* Regular use (more than twice/week) of an opioid/narcotic, benzodiazepine, or prescription sleep medication other than antidepressants currently or within the last month;\n* The use of N-acetylcysteine in any form (oral, intravenous, inhaled) in the last seven days\n* The use of other over-the-counter antioxidant therapies including vitamin C or vitamin E in the preceding 10 days\n* History of reduced ejection fraction heart failure, or chronic cardiac arrhythmia requiring medication or treatment;\n* Unstable or uncontrolled medical or psychiatric comorbidity requiring hospitalization or change in medication during the previous three months;\n* Use of biologics or immune modulators in the last year;\n* Use of systemic steroids during the previous three months;\n* Current tobacco smoking;\n* Inability to sign informed consent;\n* Currently use of positive airway pressure therapy or another OSA treatment (e.g., hypoglossal nerve stimulator, oral device);\n* Recent history of alcoholism or drug abuse (within the last three months)\n* Neurological condition that requires ongoing pharmacological therapy (e.g., Parkinson's disease, Alzheimer's dementia, multiple sclerosis, other degenerative neurological disease).\n* Pregnancy",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "55 Years",
            "maximumAge": "75 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Rashmi Nisha Aurora, MD",
                    "role": "CONTACT",
                    "phone": "443-513-6535",
                    "email": "Rashmi.aurora@nyulangone.org"
                },
                {
                    "name": "Ariana Budhu",
                    "role": "CONTACT",
                    "phone": "646-501-0617",
                    "email": "Ariana.budhu@nyulangone.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Rashmi Nisha Aurora, MD",
                    "affiliation": "NYU Langone Health",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "NYU Langone Health",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10016",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: Rashmi.aurora@nyulangone.org. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP"
            ],
            "timeFrame": "Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research. Requests should be directed to Rashmi.aurora@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.",
            "accessCriteria": "The investigator who proposed to use the data will be granted access upon reasonable request."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001049",
                    "term": "Apnea"
                },
                {
                    "id": "D000012891",
                    "term": "Sleep Apnea Syndromes"
                },
                {
                    "id": "D000020181",
                    "term": "Sleep Apnea, Obstructive"
                }
            ],
            "ancestors": [
                {
                    "id": "D000012120",
                    "term": "Respiration Disorders"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                },
                {
                    "id": "D000012818",
                    "term": "Signs and Symptoms, Respiratory"
                },
                {
                    "id": "D000020919",
                    "term": "Sleep Disorders, Intrinsic"
                },
                {
                    "id": "D000020920",
                    "term": "Dyssomnias"
                },
                {
                    "id": "D000012893",
                    "term": "Sleep Wake Disorders"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M22010",
                    "name": "Sleep Apnea, Obstructive",
                    "asFound": "Obstructive Sleep Apnea",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4361",
                    "name": "Apnea",
                    "asFound": "Apnea",
                    "relevance": "HIGH"
                },
                {
                    "id": "M15694",
                    "name": "Sleep Apnea Syndromes",
                    "asFound": "Sleep Apnea",
                    "relevance": "HIGH"
                },
                {
                    "id": "M16355",
                    "name": "Syndrome",
                    "relevance": "LOW"
                },
                {
                    "id": "M14957",
                    "name": "Respiration Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15623",
                    "name": "Signs and Symptoms, Respiratory",
                    "relevance": "LOW"
                },
                {
                    "id": "M22242",
                    "name": "Parasomnias",
                    "relevance": "LOW"
                },
                {
                    "id": "M22654",
                    "name": "Sleep Disorders, Intrinsic",
                    "relevance": "LOW"
                },
                {
                    "id": "M22655",
                    "name": "Dyssomnias",
                    "relevance": "LOW"
                },
                {
                    "id": "M15696",
                    "name": "Sleep Wake Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000111",
                    "term": "Acetylcysteine"
                },
                {
                    "id": "C000030905",
                    "term": "N-monoacetylcystine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000998",
                    "term": "Antiviral Agents"
                },
                {
                    "id": "D000000890",
                    "term": "Anti-Infective Agents"
                },
                {
                    "id": "D000005100",
                    "term": "Expectorants"
                },
                {
                    "id": "D000019141",
                    "term": "Respiratory System Agents"
                },
                {
                    "id": "D000016166",
                    "term": "Free Radical Scavengers"
                },
                {
                    "id": "D000000975",
                    "term": "Antioxidants"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000020011",
                    "term": "Protective Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000000931",
                    "term": "Antidotes"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3475",
                    "name": "Acetylcysteine",
                    "asFound": "Macular",
                    "relevance": "HIGH"
                },
                {
                    "id": "M244107",
                    "name": "N-monoacetylcystine",
                    "asFound": "Band",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4314",
                    "name": "Antiviral Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4214",
                    "name": "Anti-Infective Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M8243",
                    "name": "Expectorants",
                    "relevance": "LOW"
                },
                {
                    "id": "M21137",
                    "name": "Respiratory System Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4292",
                    "name": "Antioxidants",
                    "relevance": "LOW"
                },
                {
                    "id": "M21869",
                    "name": "Protective Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4250",
                    "name": "Antidotes",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "Resp",
                    "name": "Respiratory System Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}